(0.00%) 5 187.67 points
(0.44%) 39 056 points
(-0.18%) 16 303 points
(0.34%) $79.26
(-0.23%) $2.18
(-0.31%) $2 315.10
(-0.17%) $27.56
(0.01%) $984.70
(0.07%) $0.931
(0.11%) $10.90
(0.06%) $0.801
(0.01%) $91.75
Quarter results today
(amc 2024-05-09)
Expected move: +/- 6.70%
@ $8.22
发出时间: 14 Feb 2024 @ 22:30
回报率: 23.84%
上一信号: Feb 13 - 22:30
上一信号:
回报率: -2.26 %
Live Chart Being Loaded With Signals
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients...
Stats | |
---|---|
今日成交量 | 621 967 |
平均成交量 | 819 065 |
市值 | 529.44M |
EPS | $0 ( 2024-02-28 ) |
下一个收益日期 | ( $-0.190 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.88 |
ATR14 | $0.0160 (0.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-01 | Novack Jeffrey Adam | Sell | 1 905 | Common Stock |
2024-04-24 | Novack Jeffrey Adam | Sell | 0 | Common Stock |
2024-04-24 | Novack Jeffrey Adam | Sell | 2 385 | Employee Stock Option (right to buy) |
2024-04-24 | Novack Jeffrey Adam | Sell | 2 150 | Employee Stock Option (right to buy) |
2024-05-01 | Jain Abhishek | Sell | 7 371 | Common Stock |
INSIDER POWER |
---|
8.60 |
Last 100 transactions |
Buy: 1 531 623 | Sell: 918 597 |
音量 相关性
CareDx Inc 相关性 - 货币/商品
CareDx Inc 财务报表
Annual | 2023 |
营收: | $280.32M |
毛利润: | $175.87M (62.74 %) |
EPS: | $-3.54 |
FY | 2023 |
营收: | $280.32M |
毛利润: | $175.87M (62.74 %) |
EPS: | $-3.54 |
FY | 2022 |
营收: | $321.79M |
毛利润: | $209.58M (65.13 %) |
EPS: | $-1.440 |
FY | 2021 |
营收: | $296.40M |
毛利润: | $199.01M (67.14 %) |
EPS: | $-0.582 |
Financial Reports:
No articles found.
CareDx Inc
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。